Bromide

Bromide

SCHEMBL1159786

Br.Cc1ccc(S(=O)(=O)N2CCCNCCC2)cc1

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.72
ALDH1A1 P00352 4/20 0.72
HTT P42858 3/20 0.72
POLB P06746 1/20 0.72
LMNA P02545 3/20 0.65
KMT2A Q03164 4/20 0.64
MEN1 O00255 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
HSD17B10 Q99714 1/20 0.57
USP2 O75604 1/20 0.56
GAA P10253 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
MAPT P10636 1/20 0.54
KDM4E B2RXH2 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217199 0.98 PKM (0.74) PKMALDH1A1HTTPOLBLMNA
SCHEMBL1956663 0.95 ALDH1A1 (0.70) PKMALDH1A1HTTPOLBLMNA
SCHEMBL3111901 0.92 ALDH1A1 (0.76) PKMALDH1A1HTTPOLBLMNA
Aziridine SCHEMBL22778235 0.92 KMT2A (0.76) PKMALDH1A1HTTPOLBLMNA
SCHEMBL1259378 0.91 PKM (0.69) PKMALDH1A1HTTPOLBLMNA
SCHEMBL3976265 0.90 PKM (0.69) PKMALDH1A1HTTPOLBLMNA
Bromide SCHEMBL3967182 0.88 MAPT (0.65) PKMALDH1A1HTTPOLBLMNA
Bromide SCHEMBL3970603 0.88 PKM (0.69) PKMALDH1A1HTTPOLBLMNA
SCHEMBL5955341 0.88 MAPT (0.69) PKMALDH1A1HTTPOLBLMNA
SCHEMBL651924 0.88 MAPT (0.69) PKMALDH1A1HTTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394789-B2 (Dihydro)pyrrolo[2,1-α]isoquinolines MSD OSS B.V. (NL) 2013-03-12 US disclosed
EP-2252611-B1 (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES ORGANON NV (NL) 2011-10-05 EP disclosed
US-20110039832-A1 DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES N.V. ORGANON (NL) 2011-02-17 US disclosed
EP-2252611-A1 (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES N.V. Organon (NL) 2010-11-24 EP disclosed
WO-2009098283-A1 (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES N.V. ORGANON (NL) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039832-A1 DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES PKD2, PKD1, CATSPER1 PKM 1292/4885ALDH1A1 96/4885HTT 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.